Date: 2011-04-01
Type of information: Capital increase
Company: Thrombogenics (Belgium)
Investors: employees
Amount: € 173 340
Funding type: capital increase arising from employee warrant exercises
Planned used:
Others: ThromboGenics has announced a capital increase arising from employee warrant exercises. Since its inception in 2006, ThromboGenics has used warrant plans to incentivize personnel and management and have them share in the success of the company. Following warrant exercises during the exercise period in March 2011, ThromboGenics issued 24,000 new ordinary shares on 25 March 2011 for a total capital increase (including issuance premium) of €173,340. To date, ThromboGenics total share capital amounts to €145,843,837.46; the total number of securities conferring voting rights is 32,413,757 which is also the total number of voting rights. All voting rights are of the same category.
Therapeutic area: Ophtalmological diseases
